Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient
Andrea Boutros(The University of Sydney), Paola Queirolo, Giuseppe Murdaca(Ospedale Policlinico San Martino), Francesco Spagnolo(Ospedale Policlinico San Martino), Francesca Giusti(University of Genoa), Chiara Schiavi(Ospedale Policlinico San Martino), Enrica T. Tanda(Ospedale Policlinico San Martino), Federica Cecchi(Ospedale Policlinico San Martino), Antonio Guadagno(Ospedale Policlinico San Martino)
Cited by 15
Related Papers
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|388
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
|Nature Genetics|2020|238
The treatment of advanced melanoma: Current approaches and new challenges
|Critical Reviews in Oncology/Hematology|2024|140
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy
|Seminars in Cancer Biology|2019|119